Discounted Cash Flow Calculation for NSEI:THYROCARE using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method. We use
analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
NSEI:THYROCARE DCF 1st Stage: Next 5 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Thyrocare Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
Thyrocare Technologies's earnings are expected to grow significantly at over 20% yearly.
Thyrocare Technologies's revenue is expected to grow by 15.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Thyrocare Technologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Thyrocare Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Thyrocare Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Thyrocare Technologies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Thyrocare Technologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 15.3x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. A. Velumani, Ph.D., is the Founder of Nueclear Healthcare Ltd. in 2011 and serves as its Chief Executive Officer and also has been Managing Director since April 1, 2014 and has been its Director since September 27, 2013. Dr. Velumani is the Founder, Managing Director and Chief Executive Officer of Thyrocare Technologies Limited. Mr. Velumani served as Chief Executive Officer of Thyrocare Laboratories, Ltd. until January 17, 2011 and Eins Edutech Ltd. until January 15, 2011. Dr. Velumani is an ex Scientist from BARC. Dr. Velumani serves as a Director of Nueclear Healthcare Ltd. He is a graduate in science from the University of Madras, a post graduate in science from the University of Bombay and a Doctorate in Philosophy with science from the University of Bombay.
A.'s compensation has been consistent with company performance over the past year.
A.'s remuneration is lower than average for companies of similar size in India.
CFO & Executive Director
Head of Secretarial & Legal
Vice President of Operations
General Manager of Infrastructure
General Manager of Finance
General Manager of Business Development
Deputy General Manager of Laboratory
Deputy General Manager of Laboratory
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Thyrocare Technologies board of directors is about average.
Board of Directors
CFO & Executive Director
Non-Executive Non-Independent Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Thyrocare Technologies insiders in the past 3 months.
Interested In Thyrocare Technologies Limited (NSE:THYROCARE)? Here's How It Performed Recently
When Thyrocare Technologies Limited (NSE:THYROCARE) announced its most recent earnings (31 December 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … Did THYROCARE perform worse than its track record and industry. … Furthermore, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 19%, indicating the rate at which THYROCARE is growing has slowed down
Thyrocare Technologies Limited (NSE:THYROCARE): Commentary On Fundamentals
In the case of Thyrocare Technologies Limited (NSE:THYROCARE), there's. … is a company with great financial health as well as a. … For those interested in understanding where the figures come from and want to see the analysis,
What Can We Make Of Thyrocare Technologies Limited’s (NSE:THYROCARE) High Return On Capital?
Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … How Do You Calculate Return On Capital Employed
Do You Know What Thyrocare Technologies Limited's (NSE:THYROCARE) P/E Ratio Means?
We'll show how you can use Thyrocare Technologies Limited's (NSE:THYROCARE) P/E ratio to inform your assessment of the investment opportunity. … How Do I Calculate Thyrocare Technologies's Price To Earnings Ratio … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Want To Invest In Thyrocare Technologies Limited (NSE:THYROCARE) Today? Read This First
Thyrocare Technologies Limited (NSE:THYROCARE) is considered a high-growth stock, but its last closing price of ₹555 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … View our latest analysis for Thyrocare Technologies? … Analysts are predicting good growth prospects for Thyrocare Technologies over the next couple of years
July Insights Into Healthcare Stocks: Thyrocare Technologies Limited (NSE:THYROCARE)
is a healthcare company operating in an industry, … which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronic diseases … A focus towards more collaborative and data-driven care models, which address behavioural and physical health of chronic illness or aging patients, may help improve patient outcomes and lowered costs.
Does Thyrocare Technologies Limited's (NSE:THYROCARE) Past Performance Indicate A Stronger Future?
In this commentary, I will examine Thyrocare Technologies Limited's (NSE:THYROCARE) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, as well as how the rest of the healthcare industry performed. … Did THYROCARE's recent earnings growth beat the long-term trend and the industry. … THYROCARE's trailing twelve-month earnings (from 31 March 2018) of ₹932.75m has
With An ROE Of 21.04%, Has Thyrocare Technologies Limited's (NSE:THYROCARE) Management Done Well?
and looking to gauge the potential return on investment in Thyrocare Technologies Limited (NSE:THYROCARE). … With an ROE of 21.04%, Thyrocare Technologies Limited (NSE:THYROCARE) outpaced its own industry which delivered a less exciting 8.83% over the past year. … If THYROCARE borrows debt to invest in its business, its profits will be higher.
Thyrocare Technologies Limited (NSE:THYROCARE): A Fundamentally Attractive Investment
As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … In the case of Thyrocare Technologies Limited (NSE:THYROCARE), it
Is Thyrocare Technologies Limited (NSE:THYROCARE) Expensive For A Reason? A Look At The Intrinsic Value
I am going to run you through how I calculated the intrinsic value of Thyrocare Technologies Limited (NSEI:THYROCARE) by taking the expected future cash flows and discounting them to their present value. … 5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF (₹, Millions) ₹711.78 ₹774.33 ₹1,046.93 ₹1,710.50 ₹1,856.00 Source Analyst x4 Analyst x3 Analyst x4 Analyst x2 Analyst x2 Present Value Discounted @ 13.55% ₹626.86 ₹600.60 ₹715.15 ₹1,029.05 ₹983.37 Present Value of 5-year Cash Flow (PVCF)= ₹3,955 We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = ₹1,856 × (1 + 7.7%) ÷ (13.5% – 7.7%) = ₹34,379 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = ₹34,379 / ( 1 + 13.5%)5 = ₹18,215 The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is ₹22,170.
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. The company operates through Pathology, Radiology, and Sale of Testing Equipment and Consumables segments. It conducts medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility, and various infectious diseases. Its profiles of tests include 15 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also provides PET-CT scan imaging diagnostic services. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.